Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.59 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21076727 | 0.91 | TLR7 (0.69) | TLR7NUDT1 | |
| SCHEMBL4107236 | 0.91 | TLR7 (0.58) | TLR7NUDT1ADORA2AADORA1 | |
| SCHEMBL19539419 | 0.89 | TLR7 (0.60) | TLR7NUDT1ADORA2AADORA1 | |
| SCHEMBL3931857 | 0.89 | TLR7 (0.58) | TLR7NUDT1 | |
| SCHEMBL4099639 | 0.89 | TLR7 (0.58) | TLR7NUDT1 | |
| SCHEMBL12305185 | 0.88 | TLR7 (0.59) | TLR7 | |
| SCHEMBL509587 | 0.88 | TLR7 (0.74) | TLR7NUDT1ADORA2AADORA1 | |
| SCHEMBL4000551 | 0.88 | TLR7 (0.59) | TLR7NUDT1ADORA2AADORA1 | |
| SCHEMBL2060118 | 0.87 | TLR7 (0.69) | TLR7NUDT1 | |
| SCHEMBL21076908 | 0.86 | TLR7 (0.56) | TLR7NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611268-B2 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611268-B2 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611268-B2 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20150239888-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150239888-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150239888-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. | 2015-08-27 | — | — | US | disclosed |
| EP-2170888-B1 | PURINE DERIVATIVES AND THEIR USE AS MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES INC (US) | 2015-04-22 | — | — | EP | disclosed |
| EP-2170888-B1 | PURINE DERIVATIVES AND THEIR USE AS MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES INC (US) | 2015-04-22 | — | — | EP | disclosed |
| US-8993755-B2 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2015-03-31 | — | — | US | disclosed |
| US-8993755-B2 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2015-03-31 | — | — | US | disclosed |
| US-20110236348-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-7968544-B2 | Agonists; Treatment of Hepatitis C virus; purine derivatives | GILEAD SCIENCES, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968544-B2 | Agonists; Treatment of Hepatitis C virus; purine derivatives | GILEAD SCIENCES, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968544-B2 | Agonists; Treatment of Hepatitis C virus; purine derivatives | GILEAD SCIENCES, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| EP-2170888-A1 | PURINE DERIVATIVES AND THEIR USE AS MODULATORS OF TOLL-LIKE RECEPTOR 7 | Gilead Sciences, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090047249-A1 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20090047249-A1 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20090047249-A1 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2009-02-19 | — | — | US | disclosed |
| WO-2009005687-A1 | PURINE DERIVATIVES AND THEIR USE AS MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005687-A1 | PURINE DERIVATIVES AND THEIR USE AS MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047249-A1 | Modulators of toll-like receptor 7 | TLR7, TLR6, TLR3 | TLR7 1/4885NUDT1 2979/4885ADORA2A 1011/4885 |
| US-20110236348-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | TLR7, TLR6, TLR3 | TLR7 1/4885NUDT1 2653/4885ADORA2A 605/4885 |
| US-20150239888-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | TLR7, TLR6, TLR3 | TLR7 1/4885NUDT1 3085/4885ADORA2A 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.